


Molécules et Médicaments: de la découverte au développement

• Réactions de fonctionnalisation C-H et chimie médicinale


Réactions robustes de la chimie médicinale

(c) Ether formation (Williamson synthesis / Mitsunobu reaction)




X = Leaving Group, e.g. Br, I

(e) Sulphonamide formation




(j) Wittig reaction



Other reaction types


Electrophilic reactions of amines



Amine Boc-deprotections




Aromatic nucleophilic substitution reaction (S_NAr)




In drug discovery “robust reactions” are reproducible chemical transformations with the following characteristics:

- Provide structures relevant for drug discovery
- Technically straightforward (no special equipment needed)
- Moderately sensitive to reaction parameters
- Broad availability of starting materials and reagents
- Broad functional group tolerance including polar functionalities
- Time for delivery of the target compounds is reasonably short

Amide formation



Suzuki–Miyaura reaction



Molécules et Médicaments: *de la découverte au développement*

- Réactions de fonctionnalisation C-H et chimie médicinale

Late-stage functionalization

Tactic 1: Hydroxylation

Hydroxylation can for example provide improved activity, selectivity, solubility and lipophilicity. Reduction in lipophilicity can improve metabolic clearance, although increased rates of Phase II metabolism (e.g. glucuronidation) can occur. Quite a few chemical and biochemical and hydroxylation methods are emerging.

Tactic 2: Methylation


Strategic methylation can produce compounds with pronounced improvements in activity, safety and DMPK properties. New late stage methylation methods with regio- or stereochemical control could have great utility for this purpose.

Tactic 3: Fluorination

Aromatic fluorination is a common strategy to reduce metabolic liabilities and improve biological activity. The fluorine can serve to block C-H “hot-spots” susceptible to P450 oxidation. Aliphatic fluorines can reduce lipophilicity, modulate the pKa of ionisable centers and add conformational rigidity to structures.

Tactic 4: Necessary nitrogens

The ubiquity of nitrogen heterocycles in drug molecules reflects their importance in molecular recognition and property modulation.⁵ New methods compatible with the presence of aromatic nitrogens in intermediates, enables the production of diverse and functionalized hydrophilic compounds.



- ✓ Atom and step economy
- ✓ Amounts of waste
- ✓ Selectivity
- ✓ FG tolerance

> *An infinite choice of starting materials*

C-H bonds are found in nearly all organic compounds.

> *C-C, C-O, C-N, C-B, C-Si Bond Forming Reactions*

> *New retrosynthetic strategies*

> *Structural core diversification*

Molécules et Médicaments: *de la découverte au développement*

• Réactions de fonctionnalisation C-H et chimie médicinale

Réactions de fonctionnalisation C-H: challenges

- Reactivity

High enthalpic stability of C-H bonds : Most of them are stronger than the corresponding C-X bonds

> Therefore a C-H functionalization is thermodynamically unfavored.


Alkanes > not strongly nucleophilic.

> not highly electrophilic or sensitive to light.

> The challenge in C-H functionalization is attributable to a high kinetic barrier to reaction.

Bond	Bond Dissociation Energy kcal/mol [kJ/mol]
C—H	99 [413]
C—C	83 [347]
C—N	73 [305]
C—O	86 [358]
C—Cl	81 [339]

BDEs of C—H Bonds (kcal mol⁻¹)



Source: Blanksby, S. J.; Ellison, G. B. *Acc. Chem. Res.* **2003**, 36, 255–263.

- Selectivity

1. In most molecules, more than one C-H bond of a certain type, and more than one type of C-H bond exist.

> Therefore, a catalyst should exert high selectivity towards one particular type of C-H bond.

2. Once the desired C-X bond is formed (for example, a C(sp³)-OH bond), this bond itself has a lower bond strength than the C-H bond before, and over-reactions (such as alcohol oxidation to a carbonyl group) can occur.

3. Selectivity for a reaction at an unactivated C-H bond in the presence of C-H bonds that are weaker or more acidic due to a functional group

4. Control of the mono-functionalization

5. the introduction of a C-X bond might change the reactivity of a whole molecule.

Molécules et Médicaments: *de la découverte au développement*


- Réactions de fonctionnalisation C-H et chimie médicinale

Réactions de fonctionnalisation C-H: terminologie

"C-H Activation"

The replacement of a C-H bond by a C-M bond, where M is a transition metal. "Activation" in this sense means the replacement of a relatively unreactive C-H bond with a C-M bond, which can much more easily functionalized. A C-H activation followed by a reaction from C-M to C-X is therefore a key part of a C-H functionalization.

	90-105 kcal.mol ⁻¹		
<chem>c1ccccc1</chem> -H			
<chem>C=C</chem> -H			
<chem>H3C-C(=H)H</chem>	113 kcal/mol	111 kcal/mol	101 kcal/mol
<chem>H3C-C(=C)CH3</chem>			99 kcal/mol
<chem>H3C-C(=C)C(=C)CH3</chem>			97 kcal/mol
H ₃ C-M	Ru 48.5	Rh 52.0	Pd 41.6 kcal/mol
<chem>C=C</chem> -M	58.9	62.4	50.3 kcal/mol



"C-H Functionalization"

A general term describing the transformation of a C-H bond into a C-X bond. This expression is not very well defined and most general. In the following, this term is used for a C-H activation followed by a transformation to a C-X bond. A C-H activation followed by a reaction from C-M to C-X is therefore a key part of a C-H functionalization.

Molécules et Médicaments: *de la découverte au développement*


- Réactions de fonctionnalisation C-H et chimie médicinale

Réactions de fonctionnalisation C-H : activation C-H


- Mécanismes

- > 4 General mechanisms


Oxidative addition




σ-Bond metathesis



Electrophilic substitution




Base-assisted metallation



C-H Activation by Oxidative Addition

Nucleophilic C-H activation



Reverse CT (E_{CT1})
M → CH

Forward CT (E_{CT2})
M ← CH

Oxidative addition favored :
low valent electron rich transition metals Rh(I), Ir(I), Ru(0)
(d⁸ low-valent 2nd & 3rd raw late TM complexes)

posses high-energy dπ and dσ orbitals



Molécules et Médicaments: de la découverte au développement

- Réactions de fonctionnalisation C-H et chimie médicinale


C-H Activation by Oxidative Addition

Prototypical example: Reaction de Murai

Ruthenium-catalyzed *ortho*-alkylation of aromatic ketones



Iridium-catalyzed borylation > Steric control




Molécules et Médicaments: de la découverte au développement

- Réactions de fonctionnalisation C-H et chimie médicinale

C-H Activation by Electrophilic Substitution


- Mécanismes

Electrophilic C-H activation




Electrophilic substitution favored :
Electron poor, late transition metals in high oxidation states, such as Pd(II), Pt(II)

the electronic properties of the arene play a fundamental role
Works better with electron-rich arenes
Often analogous to Friedel-Crafts mechanism




C-H Activation by Concerted Metalated Deprotonation

Concerted Metallation Deprotonation (CMD)




- internal base C-H deprotonation via six-membered TS
 - little charge buildup during TS, donating ligands tolerated
 - relative basicity of C-H bond and internal base critical
 - often preceded by agostic complex formation
- (D) Tosylamide as remote directing group**





Molécules et Médicaments: *de la découverte au développement*

- Réactions de fonctionnalisation C-H et chimie médicinale

Activation C-H: Groupements directeurs



Selectivity Guidelines:



in directed $\text{Csp}^2\text{-H}$ functionalizations, activation generally occurs at the most sterically-accessible (*e*) site resulting from a 5-member chelate; electronics have little effect on reactivity






Figure 6. Directed Organometallic C–H Functionalization Selectivity Demonstrated with Acetoxylation¹


DG = Various N- and O-donor neutral and anionic groups.

- Native coordinating group



Scheme 4. Some important chemical functions that act as a monodentate directing group.

- Bidentate Directing group




Molécules et Médicaments: de la découverte au développement



- Réactions de fonctionnalisation C-H et chimie médicinale

Activation C-H: Groupements directeurs

- Aryl/vinyl halides as Directing groups
 - > The oxidative addition brings the palladium catalyst close to the C-H bond, thus facilitating the C-H activation through cyclopalladation



> The Halogen can be considered as a traceless DG






Molécules et Médicaments: de la découverte au développement

- Réactions de fonctionnalisation C-H et chimie médicinale



Réactions de fonctionnalisation C-H : insertion C-H

- Carbène-Nitrène

Neutral, divalent carbon species containing 6 valence electrons




Neutral, monovalent nitrogen species containing 6 valence electrons





Rhodium complexes are Lewis acidic and bind additional ligands at **two open axial sites**. Binding of a second ligand after addition of a first to an axial site is less favorable and **catalysis is thought to occur only at a single Rh center**. The second Rh center acts as an electron reservoir.

For a TM carbene interacting with a C-H bond:



> Stereochemical probe




Molécules et Médicaments: de la découverte au développement


- Réactions de fonctionnalisation C-H et chimie médicinale

Insertion C-H de carbènes

- Reactivity



> A COMPLETE REVERSAL IN THE REACTIVITY SCALE!!!



> Suitable for intramolecular reactions
 Issue in intermolecular processes: dimerization

> Suitable for intermolecular reactions
 The donor group has a stabilizing effect, reducing the electrophilicity of the carbene. Its lifetime is increased, thus the selectivity is improved


Molécules et Médicaments: de la découverte au développement

- Réactions de fonctionnalisation C-H et chimie médicinale



Insertion C-H de carbènes

- Selectivity

- intramolecular C-H insertion > intermolecular C-H insertion
- 5-membered ring formation > other size ring formation



> The selectivity is controlled by a combination of STERIC and ELECTRONIC factors (Intra- and Inter-molecular reactions)



Catalyst	Ratio.
$[\text{Rh}_2(\text{OAc})_4]$	37 : 63
$[\text{Rh}_2(\text{TFA})_4]$	56 : 44
$[\text{Rh}_2(\text{acam})_4]$	14 : 86
$[\text{Rh}_2(\text{Piv})_4]$	37 : 63
$[\text{Rh}_2(\text{OBz})_4]$	54 : 46
$[\text{Rh}_2(\text{OCOCHPh}_2)_4]$	64 : 36
$[\text{Rh}_2(\text{OCOCMePh}_2)_4]$	82 : 18
$[\text{Rh}_2(\text{TPA})_4]$	96 : 4
bulkier	less hindered C-H favored


Angew. Chem. Int. Ed. 1994, 33, 1797



Molécules et Médicaments: de la découverte au développement


- Réactions de fonctionnalisation C-H et chimie médicinale

Insertion C-H de nitrènes



As in the case of carbenes

> The selectivity is controlled by a combination of STERIC and ELECTRONIC factors + BDE




Concerted asynchronous insertion:

- examples: Rh
- turnover-limiting step is normally formation of iminoiodane
- three-centered transition state
- reactivity trends are dictated by the electron density of the reacting site (e.g. more electron-rich C-H bonds, such as 3°, are more reactive)

Radical C-H abstraction/rebound:






- examples: Fe, Mn, Cu, Ru, Ag, Co
- turnover-limiting step is normally C-H abstraction
- carbon-centered radical intermediate; lifetime of intermediate can be tuned by changing metal and ligand environment around metal center
- reactivity trends are dictated by the BDE of the reacting site (lower BDE = more reactive)



Molécules et Médicaments: de la découverte au développement

- Réactions de fonctionnalisation C-H et chimie médicinale

Oxydation de liaisons C-H




Molécules et Médicaments: de la découverte au développement

- Réactions de fonctionnalisation C-H et chimie médicinale


Réactions de fonctionnalisation C-H : HAT : transfert d'atome d'hydrogène

- BDE: Thermodynamic factor*



For efficient reaction, $\text{BDE}_{\text{abs}-\text{H}} > \text{BDE}_{\text{C}-\text{H}}$


BDE (kcal/mol)	97	99	101
Stability			
Selectivity of H-abstraction			



$\text{BDE}_{\text{C}-\text{H}_a} = 97$
 $\text{BDE}_{\text{C}-\text{H}_b} = 84$
 $\text{BDE}_{\text{C}-\text{H}_c} = 114$

order of reactivity
 $\text{H}^b > \text{H}^a > \text{H}^c$

all values in $\text{kcal}\cdot\text{mol}^{-1}$



Molécules et Médicaments: de la découverte au développement


- Réactions de fonctionnalisation C-H et chimie médicinale

HAT : transfert d'atome d'hydrogène


- Polarity: kinetic factor

A qualitative approach to determining the "philicity" of a radical



- Consider the oxidized (cationic) and reduced (anionic) forms of A^\bullet
- Determine which of the forms is more stable
- Assign the "philicity" of the radical:
 - If A^+ is more stable, A^\bullet is a nucleophilic radical because it wants to lose an e^-
 - If A^- is more stable, A^\bullet is an electrophilic radical because it wants to gain an e^-




Nucleophilic radicals abstract
 $\delta+$ 'protic' hydrogen atoms



Electrophilic radicals abstract
 $\delta-$ 'hydridic' hydrogen atoms




π -Bonding characteristics determine effect of heteroatom substitution



Molécules et Médicaments: de la découverte au développement

- Réactions de fonctionnalisation C-H et chimie médicinale

HAT : transfert d'atome d'hydrogène




Molécules et Médicaments: de la découverte au développement

- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : la réaction de Minisci


- Alkyl sulfinites

B. Development of zinc sulfinate toolbox for drug discovery.



R group	Acronym of zinc sulfinate reagent	Sigma-Aldrich catalog number
CF ₃	TFMS	771406
CF ₂ H	DFMS	767840
CH ₂ Cl	MCMS	791105
CH ₂ SO ₂ Ph	PSMS	792187
CF ₂ CH ₃ (Na salt)	DFES-Na	745405
CH ₂ CF ₃	TFES	745499
CH ₂ CH ₂ Cl	MCES	790788
CH ₂ CH ₂ CH ₃	NPS	791040
CH(CH ₃) ₂	IPS	745480
CH ₂ Ph	BNS	790796

A Putative mechanism.



> Alkyl sulfinites: generally nucleophilic so will react with electrophilic π -systems at their more electron-deficient sites

1. Innate Reactivity

Identify sites of innate reactivity on the parent heterocycle.




Activated positions:
 α and γ

Legend:

Size of sphere signifies the magnitude of the effect
● activating influence
● deactivating influence

2. Conjugate Reactivity




Identify sites that are made more reactive through the presence of π -electron-withdrawing groups.



Activated positions: *ortho*-*para* to conjugating EWG

3. Reactivity Modifiers

Consider the effects of other substituents and modify the reactivity of activated sites accordingly.



4. Reaction Conditions

Through choice of reaction conditions, the balance of different reactivity determining factors can be fine-tuned.

Solvent + acid

- ↑ promote innate reactivity
- ↓ reduce conjugate reactivity
- ↑ increase reactivity for electron-rich systems
- solvent usually CHCl₃/water. DMSO/acid mixtures useful for substrates with limited solubility

DMSO (neutral)

- ↓ reduce innate reactivity
- ↑ promote conjugate reactivity
- ↑ increase reactivity for electron-poor systems


CHCl₃/H₂O



enhanced δ^+ at C2

C2>>C3


DMSO



"effectively" more δ^+ at C3


C3>>C2

(i) *i*-Pr radical: nucleophilic



reactive at most δ^+ site

C2>>C3




reactive at most δ^+ site

C3>>C2



Molécules et Médicaments: de la découverte au développement

- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : Applications de la réaction de Minisci



Reactivity of fluoroalkyl radicals: $\cdot\text{CF}_3$ and $\cdot\text{CF}_2\text{H}$



Molécules et Médicaments: de la découverte au développement

- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : fluoration et méthylation








Figure 13 Use of nonbasic amine as amide isostere in the discovery of odanacatib. A second fluorine blocks the oxidation of the isopropyl group to improve pharmacokinetics.



Molécules et Médicaments: *de la découverte au développement*

- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : Propriétés physicochimiques (solubilité). Chemical Biology





Figure 1. Diversification of the lupane core by C–H oxidation.



Entry	Substrate	R ¹	Relative Solubility Enhancement: Assay 1 (FaSSIF) ^[a]
1	3	CH ₂ OH	274 ×
2	4	CH ₂ OH	8.00 ×
3	7	CH ₂ OH	121 ×
4	6	CH ₂ OH	no change
5	5	CO ₂ H	0.056 × ^[c]
6	8	CO ₂ H	0.112 × ^[c]
7	9	CO ₂ H	0.019 × ^[c]
8	10	CO ₂ H	0.002 × ^[c]




Molécules et Médicaments: de la découverte au développement

- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : Applications en diversité moléculaire



(Eliel et al., 1966; Eliel and Biros, 1966). The reason has been pointed out by Allinger et al. (1967; see also Burkert and Allinger, 1982): An equatorial alkyl group buttresses the hydrogen geminal with it and thus prevents it from bending outward. If the alkyl group is at position 3 or 5 relative to an axial substituent to be studied, this "lack of give" will increase the synaxial H/X repulsion and thus increase the conformational energy of X as well as cause other changes (Fig. 11.20).




Molécules et Médicaments: de la découverte au développement

- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : Nouvelles rétrosynthèses et SAR en chimie médicinale

(A) Retrosynthesis of (-)-quinine (Maulide)



(B) Forward synthesis





Table 1: In vivo activity of the racemic aryl analogues (\pm)-15b and (\pm)-15c and (-)-quinine hydrochloride as a reference against *P. berghei* in mice.



Substance	Dose [mg/kg]	Parasitemia reduction [%] ^[a]	Survival [days] ^[b]
(-)-quinine hydrochloride	30	42	euthanized
	100	80	7 ± 0
(\pm)-15b ^[c]	30	98	8 ± 1
	100	99	21 ± 7
(\pm)-15c ^[c]	30	0	euthanized
	100	98	7 ± 1

[a] Blood for parasitemia determination was collected on day 3 (72 h after infection). [b] Mean survival time in days ± standard deviation. Mice with a parasitemia reduction < 50% were euthanized on day 3 post-infection in order to prevent death, otherwise occurring on day 6.

[c] Purity of > 99% determined by HPLC analysis.

Molécules et Médicaments: de la découverte au développement


- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : General strategy for late-stage C-H functionalization


Guided Reaction Manifolds




1. Guided by directing groups. Catalyst or reagent is directed to an adjacent sp^2 or sp^3 C-H bond by a chelating heterocycle or functional group on the substrate. Substitution *ortho* to the directing group in sp^2 systems is most common, although many sp^3 systems as well as long-range directing groups are known.




2. Guided by sterics. Bulky catalysts drive reactivity towards sterically accessible C-H bonds. This class includes true insertion and H-abstraction reactions, as in Fig. 3, entry 1, where the substrate or catalyst are sterically encumbered. 43, 46 and 49 are bulky catalysts that override the innate reactivity of C-H bonds in 41, 44 and 47, respectively.




• Regioselectivity controlled by steric effects



Previous Work: Substrate Control



This Work: Catalyst Control



Molécules et Médicaments: de la découverte au développement


- Chimie médicinale : Développement en chimie organique

Réactions de fonctionnalisation C-H : General strategy for late-stage C-H functionalization

Innate Reaction Manifolds




1. Innate insertion or H-abstraction. Although mechanistically distinct, insertion into an electron-rich C-H bond or formation of a stable radical at an sp^3 center usually follows the same pattern of $3^\circ > 2^\circ > 1^\circ$. Reacting C-H bonds tend to be distal from electron withdrawing groups. When reagents and catalysts are large, sterics may dominate, see Fig. 4, entry 2.



2. Deprotonation of innately acidic C-H bonds. Deprotonation by strong bases can occur at sp^2 or sp^3 centers. Reactivity is driven by the acidity of the C-H bond. If directing groups steer the base to the site of reaction, see Fig. 4, entry 1.



3. Addition-elimination at innately electrophilic sp^2 carbon. Addition-elimination at an electropositive sp^2 carbon, typically with nucleophilic radicals, generally occurs on most electron deficient heterocycle. Selectivity can sometimes be perturbed by addition of acid.



4. Addition-elimination at innately nucleophilic sp^2 carbon. Addition-elimination at an electronegative sp^2 carbon follows electrophilic aromatic substitution patterns.




1. Identify which C-H bonds are possible candidates for C-H functionalization.

2. Match each C-H bond to a possible reaction manifold. Consider if reaction selectivity can be influenced by choice of reagent or catalyst.


3. Identify which functional groups or building blocks can be installed using the selected reaction manifolds.

4. Confirm the proposed products have desirable physicochemical properties and if possible perform docking studies.




• Use of visible light


> Visible Light Photoredox Catalysis



- Absorption at 452 nm (visible light)
- Stable, long-lived excited state ($\tau = 1100$ ns)
- Single electron transfer (SET) catalyst
- Effective excited state oxidant and reductant




- Max absorption at 375 nm (visible light)
- Long-lived excited state ($\tau = 1.9 \mu\text{s}$)
- Single-electron transfer catalyst
- Effective oxidant and reductant
- Triplet energy of 56 kcal mol⁻¹




• Use of visible light


> Visible Light Photoredox Catalysis



- Absorption at 452 nm (visible light)
- Stable, long-lived excited state ($\tau = 1100$ ns)
- Single electron transfer (SET) catalyst
- Effective excited state oxidant and reductant



- Max absorption at 375 nm (visible light)
- Long-lived excited state ($\tau = 1.9 \mu\text{s}$)
- Single-electron transfer catalyst
- Effective oxidant and reductant
- Triplet energy of 56 kcal mol⁻¹




• Use of visible light


> Visible Light Photoredox Catalysis

REDOX NEUTRAL REACTIONS

Scheme 39. Mechanism of the Photoredox ATRA



(A) Evidence for radical–polar crossover



> D. W.C. MacMillan *et al.*, Visible Light Photoredox Catalysis with TM Complexes, *Chem. Rev.* 2013, 113, 5322-5363

- Application of catalytic C-H Functionalization


Réactions de fonctionnalisation C-H & chimie médicinale

Total synthesis & Late-stage functionalization of natural products and drugs


• Intermolecular HAT

> Metallophotoredox catalysis

Traditional Cross-Coupling Regioselectivity Controlled by Nucleophile Pre-Activation



Catalyst Controls Selectivity Among Multiple sp³ C–H Bonds in Cross-Coupling



• Intermolecular HAT

> Metallophotoredox catalysis

